SuperworthOrganogenesis market cap ORGO
Share price times shares outstanding: what the whole company sells for, since 2017.
- Today, Oct 23, 2026
- $127.8M
- Highest close in our data
- $2.9B
- Apr 2021
Organogenesis is worth $127.8M at the close on Oct 23, 2026, at $0.99 a share.
That is down 76% over the last year and down 91% over five years.
Its highest close in our data was $2.9B in Apr 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $127.8M | $127.8M | $588.9M | −81% |
| 2025 | $670.1M | $347.6M | $787.6M | +58% |
| 2024 | $422.9M | $310.1M | $555.9M | −22% |
| 2023 | $540M | $247.9M | $567.1M | +53% |
| 2022 | $352.2M | $336.5M | $1.1B | −70% |
| 2021 | $1.2B | $824.6M | $2.9B | +46% |
| 2020 | $811.6M | $311.9M | $811.6M | +73% |
| 2019 | $468M | $42.6M | $871.9M | +693% |
| 2018 | $59M | $59M | $414.6M | −85% |
| 2017 | $384.4M | $376.6M | $388.3M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Organogenesis' size, closest first, today.
| Company | Market cap |
|---|---|
| ORGOOrganogenesis | $127.8M |
| NATRNatures Sunshine Products | $213.8M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| ATNMActinium Pharmaceuticals | $47.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| Peer median | $523.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Organogenesis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.